Literature DB >> 577360

Photocoagulation in retinal venous occlusion.

L Laatikainen.   

Abstract

Results of retinal photocoagulation therapy in 26 eyes with retinal branch vein occlusion (RBVO) and in 18 eyes with central retinal vein occlusion (CRVO) are presented. The final visual outcome in eyes with macular oedema (non-ischaemic type of occlusion) did not significantly differ from that reported in various untreated series of branch or central retinal vein occlusion. Neovascular complications in eyes with capillary non-perfusion (ischaemic type of occlusion) could not be prevented with the relatively mild photocoagulation technique (less than 200 xenon burns in CRVO) used in this study. On the basis of this series the value of photocoagulation therapy in improving the visual prognosis in venous occlusion is questionable, and, in order to prevent neovascular complications in the ischaemic type of occlusion, a more extensive treatment seems to be necessary.

Entities:  

Mesh:

Year:  1977        PMID: 577360     DOI: 10.1111/j.1755-3768.1977.tb06125.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  5 in total

1.  Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study.

Authors:  S S Hayreh; M R Klugman; P Podhajsky; G E Servais; E S Perkins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

Review 2.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

3.  The treatment of acute branch vein occlusion by photocoagulation.

Authors:  P C Wetzig
Journal:  Trans Am Ophthalmol Soc       Date:  1978

4.  Prognosis for rubeosis iridis following central retinal vein occlusion.

Authors:  S H Sinclair; E S Gragoudas
Journal:  Br J Ophthalmol       Date:  1979-11       Impact factor: 4.638

5.  Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase.

Authors:  S S Hayreh; M R Klugman; M Beri; A E Kimura; P Podhajsky
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.